Company DiaMedica Therapeutics Inc. Toronto S.E.

Equities

DMA

CA25253X2077

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

Number of employees: 19

Managers	Title	Age	Since
Rick Pauls CEO	Chief Executive Officer	52	31/03/05
Scott Kellen DFI	Director of Finance/CFO	59	31/03/18
Ambarish Shah CTO	Chief Tech/Sci/R&D Officer	-	30/04/23
Lorianne K. Masuoka CTO	Chief Tech/Sci/R&D Officer	62	01-21
James Parsons BRD	Director/Board Member	58	19/10/10
Paul Papi IRO	Public Communications Contact	-	30/11/16
Julie VanOrsdel Daves PRN	Corporate Officer/Principal	-	-
Dominic Cundari PRN	Corporate Officer/Principal	-	31/01/22
David Wambeke PRN	Corporate Officer/Principal	-	10/04/23

Members of the board	Title	Age	Since
Richard Kuntz BRD	Director/Board Member	66	29/05/23
Tanya Lewis BRD	Director/Board Member	53	28/02/23
James Parsons BRD	Director/Board Member	58	19/10/10
Michael Giuffre BRD	Director/Board Member	68	09/08/10
Rick Pauls CEO	Chief Executive Officer	52	31/03/05
Richard Pilnik CHM	Chairman	67	30/04/09
Charles Semba BRD	Director/Board Member	64	14/07/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,963,916	23,523,153 ( 61.96 %)	0	61.96 %

Name	Equities	%	Valuation
Rich Jacinto 12.01 %	4,558,823	12.01 %	12 M $
TomEnterprise AB 11.40 %	4,326,435	11.40 %	11 M $
Trill AB 10.59 %	4,021,608	10.59 %	10 M $
Vanguard Global Advisers LLC 2.670 %	1,013,522	2.670 %	3 M $
Omega Advisors, Inc. 2.328 %	883,623	2.328 %	2 M $
First Manhattan Co LLC 2.239 %	850,038	2.239 %	2 M $
David Wambeke 1.389 %	527,114	1.389 %	1 M $
Paragon Associates 1.317 %	500,000	1.317 %	1 M $
Michael Giuffre 0.8507 %	322,893	0.8507 %	816 919 $
Geode Capital Management LLC 0.6303 %	239,235	0.6303 %	605 265 $

Name	Equities	%	Valuation
Michael Giuffre -	278,282	-	704 053 $
Richard Pilnik -	119,327	-	301 897 $
Amy Burroughs -	56,132	-	142 014 $
James Parsons -	38,509	-	97 428 $
Rick Pauls -	35,804	-	90 584 $
Scott Kellen -	22,290	-	56 394 $

DiaMedica Therapeutics, Inc.

301 Carlson Parkway Suite 210

55305, Minneapolis

http://www.diamedica.com

address DiaMedica Therapeutics Inc.(DMA)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.20%	114B
REGENERON PHARMACEUTICALS, INC.	+11.54%	104B
BIONTECH SE	-13.01%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-3.47%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.97%	14.28B
SAREPTA THERAPEUTICS, INC.	+34.97%	12.55B

Bio Therapeutic Drugs